Coeptis Therapeutics Stock News

Study results demonstrate the safety and feasibility of adoptive immunotherapy using allogeneic off-the-shelf NK cells in hospitalized patients with COVID at high risk for progression of disease DVX201, the first allogeneic NK cell therapy derived from pooled donor cord blood CD34+ cells, was administered to 9 patients with no dose limiting toxicities, cytokine release syndrome or infusion toxi...

WEXFORD, Pa. , Oct. 24, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced the expansion of its license agreement with Deverra Therapeutics Inc. ("Deverra"), broadening the potential applications of its allog...

WEXFORD, Pa. , Oct. 15, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, announced that its Chief Scientific and Medical Officer Colleen Delaney, MD will attend and present at the following upcoming fall conferences.

WEXFORD, Pa. , Sept. 19, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, announced today that it has received a notification letter from the Nasdaq Hearings Panel (the "Panel") granting its request for continued listing o...

WEXFORD, Pa. , Sept. 5, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today issued a shareholder letter from its Chief Executive Officer Dave Mehalick.

Bolsters Company's Corporate Mission Financing Led by Board Member and Priced at Premium to Market Price WEXFORD, Pa. , June 20, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, is pleased to announce that it has closed on...

WEXFORD, Pa. , May 30, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced that Dr. Colleen Delaney will be attending and presenting at the Allogeneic Cell Therapies Summit 6th Annual Meeting from June 10-12 i...